( BioXyTran )Corporate Update Highlights (Previously Disclosed)ProLectin‑M (broad-spectrum antiviral platform)Bioxytran’s lead antiviral program, ProLectin‑M , is being developed under an active U.S. FDA Investigational New Drug (IND) framework, as previously announced by the Company. , is being developed under an framework, as previously announced by the Company. ( ) In May 2025, Bioxytran also announced completion of dose optimization work intended to support additional clinical trial planning and agency submissions. and associated measurement/analytical approaches previously described by the Company, including use of the , which the Company has described as an FDA-approved device to measure tissue oxygenation. Oncology research (Galectin Science)In January 2025, the Company announced a cancer-focused preprint exploring galectin‑3 modulation as a potential strategy to improve response to immune checkpoint inhibitors.